ArticlePLoS pathogens2026
HCMV encoded UL84 hijacks FHL2 to suppress type I interferon production and enhance viral replication.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virus infection activates the host's innate immune responses, which is a very precise and complex biological process and will lead to the immediate transcription of type I interferon. The general transcriptional activator proteins such as IRF3, ATF2/c-Jun, and NF-κB can be induced to form a stable enhanceosome in the transcriptional regulatory region of IFN-β promoter. Several cellular factors have recently been reported to be involved in the transcriptional regulation of IFN-β under certain physiological conditions. Here, we identified four and a half LIM domains protein 2 (FHL2) as an interacting protein of the Human Cytomegalovirus (HCMV) replication-related protein UL84 and determined that FHL2 plays an architectural role in enhancing the transcription of IFN-β induced by HCMV infection and many other viruses. Firstly, after thevirus binds to the host cell, the signal is transmitted to protein kinases, causing the cytoplasmic FHL2 to be phosphorylated and translocated into the nucleus. Then, the phosphorylated FHL2 promotes the formation of the transcription preinitiation complex (PIC) of the IFN-β promoter. Simultaneously, FHL2 is also crucial for the recruitment of TFIID to the TATA-box for initial transcription. Interestingly, during HCMV infection, HCMV replication-related protein UL84 was determined to interact with FHL2 to help the virus evade innate immune response and promote viral lytic origin (oriLyt) dependent DNA replication. Our results highlight the FHL2 as part of a signaling cascade during viral invasion, and its important regulatory effect in type I interferon synthesis, as well as provide theoretical support for the development of candidate anti-HCMV drugs acting specifically on a novel UL84 target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.